LUMO is expected to report earnings to fall 28.49% to -66 cents per share on November 12
Q3'24
Est.
$-0.67
Q2'24
Beat
by $0.24
Q1'24
Missed
by $0.30
Q4'23
Missed
by $3.04
Q3'23
Beat
by $0.11
The last earnings report on August 01 showed earnings per share of -93 cents, beating the estimate of -116 cents. With 140.98K shares outstanding, the current market capitalization sits at 30.14M.
a clinical-stage biopharmaceutical company, which engages in the development of therapeutics for the treatment of Pediatric Growth Hormone Deficiency (PGHD)